Indefinite Delivery Contract 75D30121D11352
Award Date
6/24/21
Last Date to Order
6/30/22
Federal Agency
CDC Pittsburgh
Awardee
Grifols USA LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV award is for the supply of various adult vaccines to the Centers for Disease Control and Prevention (CDC) for the period of July 1, 2023 through June 30, 2024. The contract was awarded to Grifols USA LLC, a global healthcare company specializing in the manufacturing and distribution of plasma-derived medicines and pharmaceutical supplies. The contract has a ceiling value of $1,842,400.00 and includes the supply of 12 different adult vaccines, including hepatitis,...
This indefinite-delivery, indefinite-quantity (IDIQ) contract was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, to Glaxosmithkline, LLC, a pharmaceutical company, for the purchase of 12 standard adult vaccines. The $172.4 million contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and does not utilize any set-asides. The vaccines, which include influenza, hepatitis, pneumococcal, and...
The indefinite delivery contract (IDV) with ID 75D30119D05108 was awarded to Glaxosmithkline, LLC by the Centers for Disease Control and Prevention (CDC) for the delivery of adult vaccines. The $112,644,450 multiple award contract, which does not have any set-aside designations, has a period of performance from July 1, 2019 to June 30, 2024. Under this IDV, Glaxosmithkline provides a range of pharmaceutical goods and services as the prime contractor, including influenza virus and hepatitis...
This multiple award IDV was issued by the Department of Health and Human Services Centers for Disease Control and Prevention in Pittsburgh to procure adult vaccines. Merck Sharp & Dohme LLC is the prime contractor, with a potential value of $94.3 million over the period of performance through June 2023. The IDV aims to provide various adult vaccines to the agency through the establishment of a catalog of vaccines and related services. Based on the program acronym and description, it...
The Centers for Disease Control and Prevention awarded Grifols USA LLC an indefinite delivery contract for 2019 adult vaccines. The multiple award IDC has a potential value of $1,602,700 and a period of performance from July 1, 2019 through June 30, 2020. Grifols will supply various adult vaccines to support public health programs through the CDC. As a manufacturer of pharmaceuticals and medical products, Grifols has extensive experience providing specialized drugs, vaccines, immunoglobulins and...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to supply a variety of adult vaccines over a one-year period from July 1, 2023 through June 30, 2024. The total contract ceiling value is $232,487,206.61. The contract covers the procurement of an estimated 1.5 to 3 million doses of 12 different adult vaccines, including hepatitis A, hepatitis B, hepatitis A &...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Grifols USA LLC, a global healthcare company and manufacturer of essential plasma-derived medicines and vaccines. The contract, valued at a ceiling of $12,409,500, is for the supply of 20 standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Grifols USA LLC, a large pharmaceutical manufacturer. The contract, valued at up to $13.88 million annually, is for the supply of a wide range of pediatric vaccines to support the CDC's Vaccines for Children (VFC) program. The vaccines include routine immunizations such as DTaP, Hib, hepatitis, and MMR, among others. The...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts valued at up to $25,350,000 to supply adult vaccines for the period of July 1, 2023 through June 30, 2024. The prime contractor is VBI Vaccines (Delaware) Inc. The contracts aim to procure minimum and maximum quantities of 12 adult vaccines, including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles, mumps and rubella,...
The Centers for Disease Control and Prevention (CDC) awarded a $1,727,800 indefinite delivery contract to Grifols USA LLC, a global healthcare company, to purchase 12 standard adult vaccines. The contract has a one-year period of performance from July 1, 2022 to June 30, 2023 and is not designated with any set-aside provisions. The vaccines are required to have a minimum 12-month shelf life and be delivered within 15 business days of order. The vaccines will support CDC immunization awardees,...